Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET. The presentation can be accessed via a live webcast on the company's website, with an archived version available for 90 days. Kymera's focus includes developing therapeutics that target difficult disease-causing proteins, specifically through its Pegasus platform, addressing immune-inflammatory diseases and tumors.
Details
News Market Reaction – KYMR
The recorded move for KYMR in the trading session of this news was +5.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference at 5:00 p.m. ET on Wednesday, Sept. 16, 2020.
A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. An archived webcast recording of the presentation will be available on the website for approximately 90 days.
About Kymera Therapeutics
Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.
Contact:
Investors@kymeratx.com
Bruce Jacobs
Chief Financial Officer
+1 857.285.5300
Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+1 339.970.2843
media@kymeratx.com
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
+1 202.930.4762
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.